I'll take you back to that original 5/30/24 Webcas
Post# of 154409
I think the way he describes it is much easier to understand than what you put down here.
Quote:
" Dr. Lalezari 16:29: LATCH, Stem Cell Transplant HIV Cure
In addition to these two core clinical studies, I'm pleased to announce two other exciting clinical initiatives. First, we are in discussion with the American foundation for AIDS research to partner and co-sponsor a study called LATCH, led by investigators at Oregon Health Sciences University and the University of Washington, LATCH stands for Leronlimab and Allogeneic stem cell Transplant to Cure HIV .
The proposed study will evaluate the use of leronlimab to facilitate an HIV Cure in the HIV positive subjects, undergoing stem cell transplantation. Previous reports of HIV Positive patients achieving a cure have occurred when those RARE homozygous CCR5, double negative individuals have been identified to provide donor stem cells for the transplantation.
This study will evaluate the possibility that leronlimab could extend the list of potential donors to include the much larger pool of CCR5 positive individuals. Leronlimab would be administered following transplantation for six months during the engraftment period, to protect the HIV negative, donor cells from becoming HIV infected. The hope is that those donor cells now protected from HIV infection, will then eliminate HIV from the reservoir of the transplant recipient. If successful, this study would obviously bring about much needed positive attention to both leronlimab and CytoDyn. We're exploring this partnership with AMFAR to jointly co-sponsor and fund the research aspects of the LATCH study, which importantly, will not require us to cover the cost of the transplant itself. "

